|Bid||32.61 x 900|
|Ask||32.62 x 800|
|Day's Range||31.93 - 32.63|
|52 Week Range||31.34 - 61.23|
|Beta (5Y Monthly)||0.80|
|PE Ratio (TTM)||7.95|
|Forward Dividend & Yield||1.03 (3.21%)|
|Ex-Dividend Date||May 10, 2021|
|1y Target Est||N/A|
The U.S. Food and Drug Administration (FDA) on Wednesday classified an expanded recall of certain ventilators by Philips late last year as Class 1, or the most serious type, saying they could lead to injuries or death. The Dutch medical equipment company initiated the recall of 215 Trilogy Evo ventilators and 51 repair kits in the United States in December due to potential health risks from a type of foam used in the devices. So far, there have been no reported injuries or deaths from the products, which were distributed in the United States and Korea, the FDA said.
Roche Holding, Pfizer, Baxter International, STMicro and Philips are included in this analyst blog.